Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the ...
Berenberg Bank analyst Luisa Hector maintained a Buy rating on Merck & Company (MRK – Research Report) yesterday and set a price ...
Merck has been in pursuit of eligible candidates that could potentially make up for a loss of revenue from its aging ...
PRNewswire/ -- "According to the latest BCC Research study, "The global ADCs market is showing a rapid growth trend, with growth rates of 36.5% and 40.7% ...
The Bioprocessing Market share is expected to reach US$ 72.55 billion by 2031 from US$ 25.35 billion in 2023 to record a CAGR ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE. In this ...
We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where ...
Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...
Merck & Co., Inc. (MRK) announced the positive results from the Phase 2b/3 clinical trial (MK-1654-004) evaluating clesrovimab, the ...
Investors can either buy these names or call options on them.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback